Xiu-Mei Yang1, Yue-Xiang Zhao2, Zong-Hua Wang1, Lu Liu1. 1. Department of Ophthalmology, PLA Army General Hospital, Beijing 100700, China. 2. Department of Cardiology, Nanlou Clinical Division of Chinese PLA General Hospital, Beijing 100853, China.
Abstract
AIM: To evaluate the effect of intravitreal ranibizumab injection for retinopathy of prematurity (ROP) in Zone II Stage 3+. METHODS: Data was collected for ROP patients with Zone II Stage 3+ who received intravitreal ranibizumab injections between October 2014 and Janu-ary 2017 at the Department of Ophthalmology in our hospital. No prior laser or other intravitreal treatment was done. Prior to the intervention and at each follow-up visit, fundus examination was performed. Gestational age at birth, sex, birth weight, ROP zone, ROP stage, post menstrual age (PMA) at treatment, and follow-up pe-riod were recorded. The final clinical status of the retina was evaluated for each patient. The primary outcome mea-sures included ROP recurrences requiring re-treatment, complete or incomplete peripheral vascularization. RESULTS: Eighty-six eyes of 46 premature infants with Zone II Stage 3+ ROP were enrolled in the study. The mean gestational age at birth was 28.18±1.67 (range: 25 to 33)wk and the mean birth weight was 1070.57±226.85 (range: 720.00 to 1650.00) g. The mean PMA at treatment was 38.32±2.99 (range: 32.29 to 46.00)wk. Seventy-one eyes (82.56%) were treated success-fully with intravitreal ranibizumab as monotherapy. Fifteen eyes (17.44%) developed recurrent disease. The mean interval between the treatment and retreatment was 5.96±3.22 (range: 1.86 to 11.71)wk. All eyes vascularized into zone III at the end of the study and among them 62 eyes (72.09%) achieved complete vascu-larization. CONCLUSION: Intravitreal ranibizumab injection is an effective treatment in Zone II Stage 3+ ROP patients. More patients with longer follow-up duration are necessary to confirm the safety and efficacy of this treatment.
AIM: To evaluate the effect of intravitreal ranibizumab injection for retinopathy of prematurity (ROP) in Zone II Stage 3+. METHODS: Data was collected for ROP patients with Zone II Stage 3+ who received intravitreal ranibizumab injections between October 2014 and Janu-ary 2017 at the Department of Ophthalmology in our hospital. No prior laser or other intravitreal treatment was done. Prior to the intervention and at each follow-up visit, fundus examination was performed. Gestational age at birth, sex, birth weight, ROP zone, ROP stage, post menstrual age (PMA) at treatment, and follow-up pe-riod were recorded. The final clinical status of the retina was evaluated for each patient. The primary outcome mea-sures included ROP recurrences requiring re-treatment, complete or incomplete peripheral vascularization. RESULTS: Eighty-six eyes of 46 premature infants with Zone II Stage 3+ ROP were enrolled in the study. The mean gestational age at birth was 28.18±1.67 (range: 25 to 33)wk and the mean birth weight was 1070.57±226.85 (range: 720.00 to 1650.00) g. The mean PMA at treatment was 38.32±2.99 (range: 32.29 to 46.00)wk. Seventy-one eyes (82.56%) were treated success-fully with intravitreal ranibizumab as monotherapy. Fifteen eyes (17.44%) developed recurrent disease. The mean interval between the treatment and retreatment was 5.96±3.22 (range: 1.86 to 11.71)wk. All eyes vascularized into zone III at the end of the study and among them 62 eyes (72.09%) achieved complete vascu-larization. CONCLUSION: Intravitreal ranibizumab injection is an effective treatment in Zone II Stage 3+ ROP patients. More patients with longer follow-up duration are necessary to confirm the safety and efficacy of this treatment.
Entities:
Keywords:
plus disease; ranibizumab; retinopathy of prematurity
Authors: Brian A Darlow; Anna L Ells; Clare E Gilbert; Glen A Gole; Graham E Quinn Journal: Arch Dis Child Fetal Neonatal Ed Date: 2011-12-30 Impact factor: 5.747
Authors: Cassie A Ludwig; Tiffany A Chen; Tina Hernandez-Boussard; Andrew A Moshfeghi; Darius M Moshfeghi Journal: Ophthalmic Surg Lasers Imaging Retina Date: 2017-07-01 Impact factor: 1.300
Authors: David K Wallace; Raymond T Kraker; Sharon F Freedman; Eric R Crouch; Amy K Hutchinson; Amit R Bhatt; David L Rogers; Michael B Yang; Kathryn M Haider; Deborah K VanderVeen; R Michael Siatkowski; Trevano W Dean; Roy W Beck; Michael X Repka; Lois E Smith; William V Good; Mary Elizabeth Hartnett; Lingkun Kong; Jonathan M Holmes Journal: JAMA Ophthalmol Date: 2017-06-01 Impact factor: 7.389
Authors: Maria A Martínez-Castellanos; Ana González-H León; Juan C Romo-Aguas; Luis A Gonzalez-Gonzalez Journal: Graefes Arch Clin Exp Ophthalmol Date: 2020-01-17 Impact factor: 3.117
Authors: Elçin Süren; Dilek Özkaya; Ersan Çetinkaya; Mustafa Kalaycı; Kenan Yiğit; Mehmet Fatih Kücük; Muhammet Kazim Erol Journal: Int Ophthalmol Date: 2022-01-30 Impact factor: 2.031
Authors: Rania M Bassiouny; Walid M Gaafar; Amgad El Nokrashy; Ameera G Abdelhameed; Eman A Attallah; Ahmed G Elgharieb; Mohamed R Bassiouny Journal: Eye (Lond) Date: 2021-10-28 Impact factor: 4.456
Authors: Akiyoshi Uemura; Marcus Fruttiger; Patricia A D'Amore; Sandro De Falco; Antonia M Joussen; Florian Sennlaub; Lynne R Brunck; Kristian T Johnson; George N Lambrou; Kay D Rittenhouse; Thomas Langmann Journal: Prog Retin Eye Res Date: 2021-02-25 Impact factor: 21.198